News
ADVI in the News
ADVI Leaders Share IRA Insights with Managed Healthcare Executive
"Right now may not be the best time to move forward with the Inflation Reduction Act (IRA) as it could increase inflation through 2024." This was just one key insight that ADVI's Marc Samuels, CEO and president and Lindsay Bealor Greenleaf, vice president and head of policy and reimbursement shared with Managed Healthcare Executive. Read more about what this new law could mean for the healthcare industry and long-term innovation moving forward.
Louis Jacques Discusses New Drug Approvals and Reimbursement with Pink Sheet
ADVI's Louis Jacques, chief clinical officer, sat down with the Pink Sheet to discuss how FDA and CMS are working to ensure a smooth handoff from new drug approval to reimbursement.
ADVI Expert Speaks With Modern Healthcare About What the IRA Means for PBMs
ADVI's Lindsay Bealor Greenleaf, vice president and head of policy and reimbursement, is featured in Modern Healthcare in an in-depth conversation on what the Inflation Reduction Act (IRA) means for PBMs. Read the full article to hear from Lindsay and other experts in the field have to say
ADVI Discusses Implications of New Drug Price Bill with Bloomberg Law
ADVI expert Lindsay Bealor Greenleaf, vice president and head of policy and reimbursement, sat down with Bloomberg Law to discuss how the new drug pricing bill might shift dollars away from cancer meds. “Under this bill, there is no incentive to research new indications or new formulations of existing drugs. Period. Because you don’t have the opportunity to restart that thirteen-year clock for biologics or nine-year clock for small molecules.” Hear more from Lindsay and other experts on this topic.
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.